Related references
Note: Only part of the references are listed.Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom
Vivek C. Goodoory et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis
Christopher J. Black et al.
GUT (2022)
Editorial: work and activity impairment are important considerations to optimise treatment plans for irritable bowel syndrome
Eric D. Shah et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Impact of Rome IV Irritable Bowel Syndrome on Work and Activities of Daily Living
Vivek C. Goodoory et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)
Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care
Christopher J. Black et al.
GUT (2021)
Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis
Christopher J. Black et al.
GUT (2020)
Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis
Christopher J. Black et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis
Christopher J. Black et al.
GUT (2020)
Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis
Christopher J. Black et al.
GASTROENTEROLOGY (2018)
Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms?
Alexander C. Ford et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)